This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Rosiglitazone

This study has been completed.
Information provided by:
University Hospital, Montpellier Identifier:
First received: January 31, 2006
Last updated: October 5, 2006
Last verified: January 2006

To evaluate :

  • acute effects of a single dose of 8 mg rosiglitazone (therapeutic dose)
  • on insulin secretion and
  • insulin sensitivity in 12 healthy male subjects.

Condition Intervention
Healthy Drug: rosiglitazone

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Assessment of the Effect of Rosiglitazone on Insulin Secretion in Healthy Volunteers

Resource links provided by NLM:

Further study details as provided by University Hospital, Montpellier:

Primary Outcome Measures:
  • insulin response and insulin sensitivity assessed by 2-hours 10 mmol/l hyperglycemic clamp, started 45 min after treatment intake

Secondary Outcome Measures:
  • insulin clearance
  • basal glycemia and insulinemia
  • tolerance

Estimated Enrollment: 12
Study Start Date: June 2004
Estimated Study Completion Date: November 2004

Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • BMI between 18.0 and 24.0

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00285142

Centre d'Investigation Clinique
Montpellier, France, 34295, cedex 5
Sponsors and Collaborators
University Hospital, Montpellier
Principal Investigator: PIERRE PETIT, MD-PhD Centre d'Investigation Clinique
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00285142     History of Changes
Other Study ID Numbers: UF7715
Study First Received: January 31, 2006
Last Updated: October 5, 2006

Keywords provided by University Hospital, Montpellier:
insulin secretion
clinical trial

Additional relevant MeSH terms:
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on September 21, 2017